Cytokinetics Inc. (CYTK) Trading Down 1.8%
Cytokinetics Inc. (NASDAQ:CYTK) shares traded down 1.8% during trading on Monday . The stock traded as low as $10.11 and last traded at $10.14, with a volume of 94,192 shares changing hands. The stock had previously closed at $10.33.
Several research analysts have commented on the stock. FBR & Co reissued a “buy” rating on shares of Cytokinetics in a report on Monday, May 2nd. Zacks Investment Research downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Roth Capital reissued a “buy” rating on shares of Cytokinetics in a report on Saturday, April 30th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $24.00 price objective on shares of Cytokinetics in a report on Wednesday, May 25th. Eight research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $17.38.
The company’s 50-day moving average price is $8.77 and its 200 day moving average price is $7.99. The firm’s market capitalization is $399.78 million.
Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. On average, analysts expect that Cytokinetics Inc. will post ($1.50) earnings per share for the current year.
Several hedge funds and institutional investors have recently modified their holdings of CYTK. Russell Frank Co purchased a new position in shares of Cytokinetics during the fourth quarter worth $4,719,000. EAM Investors LLC purchased a new position in shares of Cytokinetics during the fourth quarter worth $4,388,000. Matarin Capital Management LLC purchased a new position in shares of Cytokinetics during the fourth quarter worth $2,512,000. Finally, GSA Capital Partners LLP increased its position in shares of Cytokinetics by 532.5% in the fourth quarter. GSA Capital Partners LLP now owns 117,931 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 99,287 shares during the period.
Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.